Stocklytics Platform
Asset logo for symbol ACCD
Accolade
ACCD52
$6.98arrow_drop_up0.07%$0.00
Asset logo for symbol ACCD
ACCD52

$6.98

arrow_drop_up0.07%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Accolade (ACCD) Stocklytics Forecast

Accolade Inc (ACCD) is an innovative healthcare technology company that provides personalized, data-driven solutions to improve the healthcare experience for individuals and their employers. With a unique combination of AI and machine learning algorithms, Accolade is revolutionizing the way healthcare is delivered and managed. As a result, the company has garnered significant attention from investors and analysts alike, who are eagerly anticipating its future performance.
When it comes to the stock price prediction for Accolade Inc (ACCD), analysts and AI algorithms have provided varying forecasts. While it is always important to consider multiple sources of information, it is worth noting some of the key trends and factors that may influence the stock's future performance.
add Accolade  to watchlist

Keep an eye on Accolade

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Accolade (ACCD) stock?

Analysts have set a target price of $14.83 for Accolade (ACCD), based on forecasts from 29 analysts. The predicted price range extends from a high of $18 to a low of $10. This represents a potential increase of up to 157.88% and a decrease of 43.27% from the current price of $6.98. These forecasts are as of 2023 Jun 26.
help

What are the analyst ratings for Accolade (ACCD) stock?

Currently, there are no analyst ratings available for Accolade (ACCD), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Accolade (ACCD) stock?

At present, there is no AI or machine-learning-based price prediction available for Accolade (ACCD) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level